Department of Radiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3685-3692. doi: 10.31557/APJCP.2021.22.11.3685.
The association between ABO blood group and the prognosis of hepatocellular carcinoma (HCC) remains unclear. We investigated the impact of ABO blood groups as a prognostic factor in HCC patients treated with transarterial chemoembolization (TACE).
We revisited records of all HCC patients who underwent TACE between January 2007 and December 2019 at a tertiary care hospital. The inclusion criteria were HCC patients, Child-Pugh score A5-B7, and treated with TACE monotherapy. The baseline characteristics of each patient were compared against their blood group and the survival analysis was carried out using Cox's regression. With Bonferroni adjustment for multiple comparisons, P-values <.0125 were considered statistically significant.
Of 211 eligible patients, the frequencies of blood groups O, A, B, and AB were 89, 54, 56, and 12, respectively. Their respective months of median survival were 41, 20, 21, and 42. After adjustments in the six-and-twelve criteria and Child-Pugh scores, and using blood group O as the referent group, the coefficients (SE) of groups A, B, and AB were 0.69 (0.24), 0.47 (0.23), and 0.49 (0.49), respectively. A significant difference in survival was found only between patients with blood group O vs A (hazard ratio, 2.00; confidence interval, 1.25-3.21).
ABO blood group is associated with the prognosis of HCC patients treated with TACE monotherapy. In our data, patients with blood group O tended to have the best survival. However, only blood group A patients had a significantly shorter survival rate comparing to blood group O.
ABO 血型与肝细胞癌（HCC）的预后之间的关系尚不清楚。我们研究了 ABO 血型作为接受经动脉化疗栓塞（TACE）治疗的 HCC 患者的预后因素的影响。
我们回顾了 2007 年 1 月至 2019 年 12 月在一家三级护理医院接受 TACE 治疗的所有 HCC 患者的记录。纳入标准为 HCC 患者，Child-Pugh 评分 A5-B7，且接受 TACE 单一疗法治疗。将每位患者的基线特征与他们的血型进行比较，并使用 Cox 回归进行生存分析。使用 Bonferroni 调整进行多重比较，P 值<.0125 被认为具有统计学意义。
在 211 名符合条件的患者中，血型 O、A、B 和 AB 的频率分别为 89、54、56 和 12。他们的中位生存月数分别为 41、20、21 和 42。在调整了 6 个月和 12 个月的标准以及 Child-Pugh 评分后，并且以血型 O 为参照组，A、B 和 AB 组的系数（SE）分别为 0.69（0.24）、0.47（0.23）和 0.49（0.49）。仅在血型 O 与 A 患者之间发现生存差异有统计学意义（危险比，2.00；置信区间，1.25-3.21）。
ABO 血型与接受 TACE 单一疗法治疗的 HCC 患者的预后相关。在我们的数据中，血型 O 的患者倾向于有最佳的生存。然而，只有血型 A 的患者与血型 O 相比，生存率显著降低。
